Get started
Author

Kentaro Wakayama

ORCID: 0009-0002-9436-6814
Observed ORCID: 0009-0002-9436-6814
OpenAlex ID: A5043804458
Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells
2002 · Kentaro Wakayama, Sumio Ohtsuki, et al. · Neuroscience Research · 88
Blood-Brain Barrier Pharmacoproteomics-Based Reconstruction of the In Vivo Brain Distribution of P-Glycoprotein Substrates in Cynomolgus Monkeys
2014 · Yasuo Uchida, Kentaro Wakayama, et al. · Journal of Pharmacology and Experimental Therapeutics · 63
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 48
PDF
TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models
2023 · Koji Ichikawa, Satoshi Ito, et al. · Molecular Cancer Therapeutics · 11
Preclinical evaluation of targeted therapies for central nervous system metastases
2024 · Alexander J. Pfeil, Joshua D. Hale, et al. · Disease Models & Mechanisms · 10
PDF
Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.
2022 · Igor Odintsov, Allan J.W. Lui, et al. · Journal of Clinical Oncology · 8
Intracerebral Distribution of Drugs with Diverse Blood–brain Barrier Transport Characteristics: In vivo Analysis using Brain Microdialysis in Cynomolgus Monkeys
2025 · Takuya Fujita, Yukari Kamikozawa, et al. · Pharmaceutical Research · 2
Abstract B157: Preclinical evaluation of the blood-brain barrier permeability and intracranial efficacy of the next-generation RET inhibitor Vepafestinib
2023 · Igor Odintsov, Kentaro Wakayama, et al. · Molecular Cancer Therapeutics · 1
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
2023 · Isao Miyazaki, Igor Odintsov, et al. · Nature Cancer · 1
PDF
Discovery of Novel Oral Covalent Inhibitors Targeting Active GTP-Bound KRASG12C with Potent Antitumor Activity
2026 · Juan del Pozo, Elisabeth Hennessy, et al. · Journal of Medicinal Chemistry
Supplementary Figure 2 from TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models
2024 · Koji Ichikawa, Satoshi Ito, et al.
Supplementary Figure 1 from TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models
2024 · Koji Ichikawa, Satoshi Ito, et al.
Data from TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models
2024 · Koji Ichikawa, Satoshi Ito, et al.
Data from TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models
2024 · Koji Ichikawa, Satoshi Ito, et al.
Works count: 14
Citation count: 232
H-index: 6
I10-index: 5
Year
Topic
Type